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SUMMARY. Coinfection with HIV adversely impacts every
stage of hepatitis C (HCV) infection. Liver damage in HCV
infection results from host antiviral responses rather than
direct viral pathogenesis. Despite depressed cellular immu-
nity, coinfected patients show accelerated hepatic ﬁbrosis
compared with HCV monoinfected patients. This paradox is
poorly understood. T-regulatory (Treg) cells (CD4+ and
FOXP3+) are hypothesized to limit hepatic damage in HCV.
Our hypothesis was that reduced frequency of hepatic Treg
in HIV/HCV coinfection compared with HCV monoinfection
may explain poorer outcomes. We quantiﬁed FOXP3+,
CD4+, CD8+ and CD20+ cells in liver biopsies of 35 male
subjects matched by age and ISHAK ﬁbrosis score, 12 HIV
monoinfected, 11 HCV monoinfected and 12 HIV/HCV
coinfected. Cell counts were performed using indirect
immunohistochemical staining and light microscopy. HIV/
HCV coinfected subjects had fewer hepatic FOXP3+
(P = 0.031) and CD4+ cells (P = 0.001) than HCV
monoinfected subjects. Coinfected subjects had more hepa-
tic CD8+ cells compared with HCV monoinfected
(P = 0.023), and a lower ratio of FOXP3+ to CD8+ cells
(0.08 vs 0.27, P < 0.001). Multivariate analysis showed
number of CD4+ cells controlled for differences in number
of FOXP3+ cells. Fewer hepatic FOXP3+ and CD4+ cells in
HIV/HCV coinfection compared with HCV monoinfection
suggests lower Treg activity, driven by an overall loss of
CD4+ cells. Higher number of CD8+ cells in HIV/HCV coin-
fection suggests higher cytotoxic activity. This may explain
poorer outcomes in HIV/HCV coinfected patients and
suggests a potential mechanism by which highly active
antiretroviral therapy may beneﬁt these patients.
Keywords: coinfection, FOXP3 protein, hepacivirus, HIV,
human, liver, regulatory, T-lymphocytes.
INTRODUCTION
Of 40 million people infected with HIV worldwide, approxi-
mately 25–30% are coinfected with hepatitis C virus (HCV)
[1,2]. The introduction of highly active antiretroviral ther-
apy (HAART) has signiﬁcantly improved survival of people
living with HIV [3], with HCV-related liver disease subse-
quently emerging as a major cause of morbidity and mor-
tality among coinfected patients [4–7]. Therefore,
understanding the interactions of these two viruses and
the drugs used to treat them is of vital importance.
HIV infection adversely impacts every stage of HCV
infection; enhancing HCV transmission, decreasing HCV
clearance leading to higher rates of chronic infection [8]
and to higher HCV viral loads [9]. HIV/HCV coinfected
patients have higher necro-inﬂammatory activity on
liver biopsies and earlier development of end-stage liver dis-
ease [10,11]. The mechanisms underlying this adverse
interaction are poorly understood.
Hepatic damage in HCV infection is thought to result
from host antiviral responses (including CD4+ and CD8+ T
cells) to HCV-infected hepatocytes rather than direct viral
pathogenesis [12,13]. This seems inconsistent with the
observation that while HIV/HCV coinfected patients have
worse clinical outcomes, they also have an HIV-mediated
depressed cellular immune response [14,15]. Furthermore,
data suggest that HAART-mediated HIV control limits liver
damage in HIV/HCV coinfection [16]. This paradox has, as
yet, not been fully explained.
CD4+ T-regulatory cells (Treg) play an important role in
self-tolerance and down-regulation of immune response,
having been demonstrated to decrease autoimmune
activity [17]. Forkhead box Protein 3 (FOXP3) is a
Abbreviations: FOXP3, forkhead box protein 3; HAART, highly
active antiretroviral therapy; HCV, hepatitis C virus; HIV, human
immunodeﬁciency virus.
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has been used as a marker of Treg activity [19,20]. In
HCV infection, Tregs have been associated with impair-
ment of peripheral blood immune responses and associated
with HCV chronicity [21]. HCV patients have higher levels
of Treg suppressive activity in blood compared to healthy
controls [22,23]. Ex vivo studies on hepatic tissue demon-
strate that CD4+ FOXP3+ cells are the major intrahepatic
Treg population in HCV-infected patients [24,25]. Higher
FOXP3 activity is inversely proportional to hepatic ﬁbrosis
in chronically infected patients, and so these cells have
been suggested as protective [24].
Several studies describe changes in the frequency of cir-
culating Treg in HIV infection, increasing as a relative pro-
portion of CD4+ T cells, but declining as CD4+ T-cell count
declines [25–27]. There are conﬂicting data on circulating
Treg populations in individuals infected with HCV [25,28]
and also in studies comparing HCV monoinfection with
HIV/HCV coinfection [25,29]. However, there are no data
on these regulatory cells directly from the liver in HIV/
HCV coinfection. As the liver is the primary site of pathol-
ogy and the area where Treg are substantially enriched in
HCV monoinfection, this is an important question in
understanding the enhanced pathology in HIV/HCV dis-
ease. Our primary hypothesis was that reduced frequency
of hepatic FOXP3+ Treg in subjects with HIV/HCV coinfec-
tion compared with HCV monoinfection may explain the
poorer clinical and histological outcome in the coinfected
group. We therefore analysed liver tissue from HCV mono-
infected, HIV/HCV coinfected and HIV monoinfected sub-
jects and quantiﬁed FOXP3+ T cells in relation to infection
status.
MATERIALS AND METHODS
Ethics
The protocol conforms to ethical guidelines of the Declara-
tion of Helsinki (1975), and ethical approval was granted
by the Research and Development Department of Brighton
and Sussex University Hospitals NHS Trust and the
National Research Ethics Committee (NREC). Data were
held in accordance with the Data Protection Act (1998)
and NHS Venereal Diseases Regulations (1974).
Liver tissue
Formalin-ﬁxed, parafﬁn-embedded liver biopsies from
patients seen at the Royal Sussex County Hospital, Brigh-
ton, UK, were obtained from Pathology Department
archives. These were categorized as having HIV/HCV coin-
fection, HCV monoinfection or HIV monoinfection, and 12
patients were selected from each category. Patients were
matched in terms of age (7 years) and ﬁbrosis score and
scaled to represent a range of disease stages from very mild
ﬁbrosis to cirrhosis. Due to the nature of the population
demographic, all subjects were male and non-African.
Exclusion criteria were age under 18 years of age, HIV-2
infection and hepatitis B coinfection. The rationale for liver
biopsy in patients with HCV monoinfection and HIV/HCV
coinfection was staging of their liver ﬁbrosis in relation to
hepatitis C infection. Patients in the HIV monoinfection
group were biopsied for range of non-infective, non-auto-
immune reasons, including staging of ﬁbrosis in relation to
clinical suspicion of alcoholic liver disease, non-alcoholic
fatty liver disease and nevirapine-induced liver toxicity.
Clinical data
Clinical and demographic data were obtained from hospital
notes and hospital Pathology and Clinical Biochemistry
databases.
Immunostaining and cell counts
We modiﬁed a protocol initially described by Ward et al.
[24]. All procedures were performed by investigators
blinded to the classiﬁcation of the subjects. First, six serial
sections 1.5 lm thick were cut and mounted onto
electrically charged slides (Snowcoat X-tra; Surgipath,
Eagle River, WI, USA) before oven-baking for an hour.
Next, they were pretreated at 90 °C in alkali solution for
20 min to achieve antigen-retrieval postﬁxation. Envision
FLEX Peroxidase-blocking reagent (DakoCytomation,
Glostrup, Denmark) was then applied for 5 min to block
endogenous peroxidase, preventing non-speciﬁc staining,
followed by a buffer rinse.
Primary antibody [mouse anti-human CD4, CD8, CD20
(Dako, Glostrup, Denmark) or FOXP3 (‘in house’ hybridoma
supernatant, clone 236A/E7)] was then applied to sections
for 20 min, followed by buffer rinse. Secondary anti-mouse
antibody (horseradish peroxidase; DakoCytomation) was
then applied and incubated for 20 min to achieve signal
ampliﬁcation and to improve antigen detection, followed by
buffer rinse. DAB chromagen substrate-working solution
(DakoCytomation) was then applied for 10 min to stain
bound antibody brown and then rinsed. This was followed
by application of haematoxylin (DakoCytomation) for
5 min, rinsing in water, buffer and ﬁnally water again. All
sections were stained in parallel with a negative control
which omitted the primary antibody step to ensure the spec-
iﬁcity of the antibody. The staining procedure was standard-
ized by staining slides on a Dako automated staining
machine using an EnVision (Dako) staining system.
Cell counts of portal tracts were performed on serial sec-
tions cut from the same block of liver tissue by two separate
observers blind to the clinical status of the patient. Stage of
ﬁbrosis was recorded on original collection of tissue by
Pathology Services at Brighton and Sussex University Hospi-
tals, according to original criteria set by Ishak et al. [30].
© 2013 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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Analysis was performed using SPSS version 20 (IBM, New
York, NY, USA). One-way ANOVA testing was used to
detect differences in cell count across disease groups, with
post hoc Tukey B testing used to detect signiﬁcance between
the disease groups. Multivariate logistic regression analysis
was used to test interdependence of number of FOXP3+ cells
and CD4+ cells predicting disease status. One participant
was removed as an outlier, with staining for all cell types far
exceeding other participants, and with notably high ISHAK
score and raised serum transaminases at time of biopsy.
RESULTS
Demographics
The available clinical characteristics of each study partici-
pant at time of biopsy are summarized in Table 1. Due to
the retrospective nature of the study, we were unable to
locate some data. One-way ANOVA testing demonstrated
that there was no signiﬁcant difference between disease
groups for age, ﬁbrosis score, antiretroviral medication use
in context of HIV infection, blood CD4 count or liver
function tests (Table 2). Two patients in the HIV-only
Table 1 Clinical data of study participants at time of biopsy
Age
(years) Status
Fibrosis
(ISHAK
score/6)
Blood CD4
absolute
(910
6/L)
Blood
CD4 (%)
Albumin
(g/L)
Total
bilirubin (g/L)
ALP
(IU/L)
ALT
(IU/L)
HCV
genotype
ARV
treatment
40 HIV/HCV 2 783 28 47 5 120 136 1a Yes
42 HIV/HCV 0 416 23 46 8 99 76 4d Yes
43 HIV/HCV 2 552 26 44 6 121 298 4 Yes
46 HIV/HCV 1 729 39 44 6 67 77 – Yes
44 HIV/HCV 1 264 16 48 8 148 205 2b Yes
55 HIV/HCV 2 462 22 43 8 77 69 1a Yes
47 HIV/HCV 2 240 26 46 7 73 103 1a Yes
56 HIV/HCV 1 712 35 45 10 68 71 1a Yes
53 HIV/HCV 2 231 20 43 8 59 222 1 Yes
36 HIV/HCV 4 –– 46 8 68 32 1a No
38 HIV/HCV 2 –– 47 2 103 58 – Yes
57 HIV/HCV 2 574 14 42 8 76 29 – Yes
38 HCV-only 1 –– 45 14 74 145 ––
45 HCV-only 0 –– 50 6 73 33 ––
38 HCV-only 1 –– 47 9 76 85 1 –
50 HCV-only 0 –– 45 4 82 23 1a –
42 HCV-only 1 –– 44 20 83 79 ––
53 HCV-only 2 –– 45 9 74 47 1a –
53 HCV-only 3 –– 50 14 150 64 3a –
54 HCV-only 2 –– 43 9 100 83 1a –
55 HCV-only 2 –– 43 7 74 53 ––
34 HCV-only 5 –– 47 36 63 51 1a –
45 HCV-only 6 –– 45 9 79 72 3a –
38 HIV-only 1 305 15 46 3 106 93 – Yes
44 HIV-only 0 649 26 48 18 59 51 – Yes
47 HIV-only 0 363 30 49 9 28 38 – Yes
48 HIV-only 0 908 44 51 4 107 173 – Yes
39 HIV-only 0 697 36 47 64 120 72 – Yes
53 HIV-only 2 645 22 47 9 220 22 – Yes
48 HIV-only 0 742 25 48 9 98 76 – Yes
50 HIV-only 0 761 20 46 25 96 43 – Yes
53 HIV-only 0 481 31 44 11 161 133 – Yes
41 HIV-only 3 659 31 44 12 55 127 – Yes
47 HIV-only 3 946 36 45 7 97 79 – Yes
61 HIV-only 3 457 19 44 25 122 105 – No
ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARV, antiretroviral medication.
© 2013 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
FOXP3+ cells in HIV/hepatitis C coinfection 253group were on atazanavir at time of biopsy, which is
known to cause an isolated rise in bilirubin; however, they
had serum bilirubin levels within the normal range. Of
those participants infected with HIV, the majority had
undetectable viral loads at the time of biopsy, with over
90% of them being on HAART. Of those infected with
HCV, the majority did not have HCV viral load quantiﬁed
at the time of biopsy.
FOXP3 staining cells in patients with HCV, HIV/HCV
coinfection and HIV
Our primary intention in this study was to quantify
FOXP3+ cells in portal tract tissue and in particular to look
for differences in patients with HIV/HCV coinfection com-
pared to those with HCV monoinfection. We observed that
there were signiﬁcantly fewer FOXP3 staining cells in the
portal tracts of patients with HIV/HCV coinfection when
compared with those with HCV monoinfection
(P = 0.026). In turn, there were signiﬁcantly fewer in the
HIV-only group compared to either of the HCV groups
(P < 0.001) (Figs 1 & 2; Table 3).
Relationship between disease group, FOXP3 staining
cells and CD4 staining cells
As FOXP3 cells are a subset of CD4 cells, we analysed the
number of CD4+ cells in portal tracts. Serial sections were
stained for CD4 and FOXP3 in turn. We observed that the
mean number of CD4+ cells in portal tracts in each disease
group followed the same order of magnitude as FOXP3+
cells. The HCV-only group had signiﬁcantly more CD4+
cells than either the HIV/HCV or HIV groups (P < 0.001).
The difference between either HIV group was not
signiﬁcant (P = 0.50).
In order to assess to what extent the observed differences
in frequency of FOXP3 cells in portal tracts were related to
overall changes in frequency of CD4 cells, we examined
the FOXP3/CD4 ratio in each disease group and then per-
formed multivariate analysis including both variables. We
observed that there was no signiﬁcant difference in
FOXP3/CD4 between HCV and HIV/HCV groups
(P = 0.12).
On univariate logistic regression both hepatic FOXP3
(P = 0.05) and hepatic CD4 cells (P = 0.02) predicted dis-
ease status of either HCV monoinfection or HIV/HCV coin-
fection. However, on multivariate analysis including both
variables, FOXP3 no longer independently predicted disease
status (P = 0.817), whereas CD4 remained signiﬁcant
(P = 0.036).
In summary, there is a signiﬁcant difference in the num-
ber of portal tract cells expressing FOXP3 between the
HCV and HIV/HCV groups (and indeed the HIV-only
group). This difference is largely driven by the substantial
differences in CD4+ T cells within the tissue.
Relationship between disease group, FOXP3 staining
cells and CD8 staining cells
There were signiﬁcantly more CD8+ T cells in portal tracts
of the HIV/HCV group than either the HCV group
(P = 0.023) or HIV-only group (P = 0.001) (Figs 1 & 2).
There was no signiﬁcant difference in the number of CD8+
cells between the HCV and HIV-only groups (P = 0.6).
As CD8+ cells are thought to be responsible for hepa-
tic cytotoxicity in patients with HCV, and FOXP3+ cells
responsible for immunoregulation, we examined the
FOXP3 to CD8 ratio, as an indicator for the degree of
immune control. There was a striking difference
between the HCV-only and HIV/HCV groups, with a
signiﬁcantly higher FOXP3/CD8 ratio in the HCV-
only group in comparison with the HIV/HCV group
(0.27 vs 0.08, P < 0.001).
Across disease groups, we found a positive linear rela-
tionship between FOXP3+ and CD8+ cells (r
2 = 0.16,
P = 0.018). Analysing this association within disease
groups revealed a strong positive linear association within
the HIV/HCV (r
2 = 0.468, P = 0.014) and HIV-only
(r
2 = 0.663, P = 0.001) groups and a weakly positive but
not signiﬁcant relationship in the HCV-only group
(r
2 = 0.024, P = 0.652).
Essentially, we observed that the expression of CD8+ and
FOXP3+ cells is linked and that where there are more
Table 2 Summary of clinical parameters by disease group.
Mean values in each disease group – mean age, ﬁbrosis
score, CD4 and liver function tests
Variable
(mean) HIV/HCV HCV-only HIV-only Signiﬁcance
Age (years) 46 46 47 0.90
ISHAK
score (/6)
1.8 2.1 1.0 0.19
Total
bilirubin
(g/L)
7 12 16 0.13
ALT (IU/L) 115 67 84 0.16
ALP (IU/L) 90 84 106 0.35
Blood CD4
(910
6/L)
496 – 634 0.40
Table 3 Mean cell counts in portal tracts by disease group
Mean HIV/HCV HCV-only HIV-only
FOXP3+ 15 25 3
CD4+ 38 93 24
CD8+ 203 107 74
CD20+ 30 61 13
© 2013 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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ever, in the HIV/HCV coinfected group, the overall number
of CD8+ cells is much higher and the ratio of FOXP3+ to
CD8+ cells is much lower when compared with the
HCV monoinfected group. This reﬂects that within groups
you see a reﬂex increase in FOXP3+ cells as CD8+
cells increase; however, this effect is blunted within
the coinfected group when compared with the HCV
monoinfected group.
Relationship between disease group and CD20 staining
The mean number of CD20+ cells per portal tract was sig-
niﬁcantly higher in the HCV-only group compared with
the HIV/HCV group (P = 0.048). There were fewer CD20+
cells in the HIV-only group, a difference that was signiﬁ-
cant compared with the HCV-only group (P = 0.002) but
not compared with the HIV/HCV group (P = 0.39).
DISCUSSION
The primary ﬁnding in our study is that the number of
hepatic FOXP3+ cells per portal tract was signiﬁcantly
lower in HIV/HCV coinfected patients compared with
HCV monoinfected patients. As we have previously
shown that the vast majority of FOXP3+ T cells in these
inﬁltrates are CD4+ T cells, this indicates lower number
of Treg in coinfection and therefore this population may
exhibit a lower overall level of regulatory activity. This
ﬁnding could account for the worse histological and clini-
cal outcome of these patients. Furthermore, the observa-
tion that lower number of FOXP3+ cells is accompanied
by proportionately lower number of CD4+ cells in the
HIV/HCV coinfected group suggests that lower number of
FOXP3+ cells (and therefore Treg) probably reﬂects the
lower overall number of hepatic CD4+ cells rather than a
speciﬁc loss of Treg. The observation of signiﬁcantly
P = 0.026
HIV/HCV HCV-only HIV-only
F
O
X
P
3
 
c
e
l
l
-
c
o
u
n
t
 
HIV/HCV HCV-only HIV-only
P = 0.023
C
D
8
 
c
e
l
l
-
c
o
u
n
t
 
HIV/HCV HCV-only HIV-only
C
D
2
0
 
c
e
l
l
-
c
o
u
n
t
P = 0.048
HIV/HCV HCV-only HIV-only
F
O
X
P
3
:
C
D
8
 
r
a
t
i
o
P < 0.001
Fig. 1 Mean counts of each cell type by disease group. FOXP3+ (top left), CD8+ (top right), FOXP3/CD8 ratio (bottom left)
and CD20+ staining cells (bottom right) in portal tracts divided by disease group. Signiﬁcance values for difference between
HIV/HCV and HCV-only groups (ANOVA) are shown with a P-value. Horizontal bars represent mean values.
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HIV-only group compared with either of the HCV groups
reﬂects both their immunodeﬁciency and absence of a
hepatic pathogen. This is consistent with previous studies
which have demonstrated that a higher number of
FOXP3+ cells are present in livers of HCV-infected
patients, and that FOXP3+ Treg play an important role
in this condition, compared with other causes of liver
ﬁbrosis [24]. The CD4 counts of our coinfected cohort
were relatively well preserved (mean 496) with 11 of 12
subjects being on HAART. This suggests that the loss of
regulatory activity within the liver occurs well before
signiﬁcant immunocompromise and at near normal blood
CD4 counts.
The next important ﬁnding is that the HIV/HCV coinfect-
ed group had signiﬁcantly higher number of hepatic CD8+
cells compared with the HCV-only group, and the ratio of
FOXP3+ to CD8+ cells was signiﬁcantly lower in the coin-
fected group. As CD8+ cells exhibit cytotoxic activity and
are thought to be responsible for accelerated ﬁbrosis in
HCV infection [31], this may explain the worse clinical
outcome in the coinfected group. Furthermore, as FOXP3
(Treg) is thought to down-regulate cytotoxic CD8+ T-cell
activity, the ﬁnding that the HIV/HCV group has a lower
(a) (b)
(c) (d)
(f) (e)
Fig. 2 Single immunostaining (brown stain) in serial sections of portal tract liver tissue. High FOXP3 staining in a HCV-only
patient (a) compared with lower staining in a HIV/HCV patient (b). High CD8 staining in a HIV/HCV patient (c) compared
with lower staining in a HCV-only patient (d). Staining for (e) CD4 and (f) CD20. Photographs at 409 magniﬁcation.
© 2013 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
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that this group have a lower degree of immune control
compared with the HCV-only group. Furthermore, we
observed a positive correlation between CD8+ and FOXP3+
cells across disease groups, providing evidence that expres-
sion of these cell types are closely interlinked. It suggests
that immunoregulatory intrahepatic FOXP3+ cells increase
proportionately in response to higher number of cytotoxic
CD8+ cells, albeit in smaller numbers in immunodeﬁcient
coinfected patients.
Finally, our study demonstrates that the HIV/HCV coin-
fected group had signiﬁcantly fewer hepatic CD20+ cells
than the HCV monoinfected group. As CD20 is a marker
for B cells, this ﬁnding suggests impaired humoral immu-
nity in the coinfected group. Furthermore, B cells have
been shown to play a regulatory role although the nature
of this in HCV has not been established [32]. This provides
evidence of alternate mechanisms in which HIV infection
may impair immunity in the context of HCV and thus lead
to poorer outcomes in coinfected patients.
This is a preliminary retrospective study and as such is
limited by the number and types of assays that could be
performed. Using immunohistochemistry on archived liver
tissue, we have shown the inter-relatedness of FOXP3+
and CD8+ cells and their importance in HIV/HCV coinfec-
tion. Further studies including ﬂow cytometry are war-
ranted on fresh liver samples with concomitant assays on
peripheral blood mononuclear cells. While FOXP3 remains
a preferred marker for Treg, the isolation of these cells in
human tissue remains a challenge due to the possibility of
heterogeneity in surface proteins [33]. Other authors have
suggested CD4+ CD25+ cells that have low CD127 expres-
sion as an alternate marker; however, further studies are
required before deciding on a deﬁnitive marker for Treg
[34]. Furthermore, the liver tissue available in our histol-
ogy archive limited the spectrum of disease that could be
studied. While we have matched samples from HIV/HCV
coinfected individuals and HCV monoinfected cases by
ﬁbrosis score (as well as age and gender), these ﬁndings
need to be replicated in a larger, prospective, multicentre
study that would also include female participants and
different ethnicities in order for these results to be
generalisable.
In conclusion, our study provides novel data on the bal-
ance between intrahepatic T-cell populations in patients
coinfected with HIV and HCV. The worse clinical and his-
tological outcome in coinfected patients despite their
immunodeﬁciency has long been at odds with dominant
understanding that hepatic damage is a consequence of
immune overactivity. Due to the observational nature and
temporal limitations of our study, we are unable to attri-
bute causality; however, our data supports a theory that
in the context of HCV infection, HIV infection decreases
number of FOXP3+ CD4+ Treg cells, leading to decreased
immunoregulation and increased pathology due to cyto-
toxic CD8+ T-cell populations. Early HAART is recom-
mended in patients with coinfection, and this study
provides a plausible mechanism as to how this might pro-
vide beneﬁt, that is if HAART can be started before CD4
cell numbers decline, then Treg numbers and immune reg-
ulatory activity may be preserved. The fact that liver regu-
latory activity appears to be depressed in coinfected
patients, even with relatively well-preserved CD4 counts,
suggests that very early HAART may beneﬁt this group.
This would therefore support the rationale for initiating
HAART earlier in patients with HIV/HCV coinfection. This
could serve to reduce HCV disease progression though in
this retrospective study we are not able to demonstrate
this. It would have been interesting to study patients with
lower CD4 counts and those not on HAART. However, in
the modern antiretroviral era, there are few of these
patients in cohorts, particularly given the trend to start
early HAART in hepatitis virus coinfected patients. Finally,
our data suggest that in this coinfected population, HIV
infection also has a detrimental effect on number of
CD20+ cells, thus potentially weakening local humoral
immunity. We believe our ﬁndings may explain in part
why coinfected patients have a worse overall outcome and
propose that future prospective studies of FOXP3 cells
in these populations may be of value in deﬁning disease
progression.
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